P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION

作者
Chen Liang,Yi He,Aiming Pang,Donglin Yang,Rongli Zhang,Weihua Zhai,Xiaojin Wu,Sizhou Feng,Mingzhe Han,Erlie Jiang
出处
期刊:HemaSphere [Wolters Kluwer]
卷期号:7 (S3): e49346c4-e49346c4 被引量:2
标识
DOI:10.1097/01.hs9.0000971936.49346.c4
摘要

Topic: 22. Stem cell transplantation - Clinical Background: Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) with FLT3-Internal Tandem Duplication (ITD) mutation have a poor prognosis and high risk of relapse, even after allogeneic hematopoietic stem cell transplantation (HSCT). Prevention of disease relapse remains a challenge. Aims: To investigate the efficacy and tolerability of gilteritinib maintenance therapy post-transplantation in r/r AML patients with FLT3-ITD mutation. Methods: We compared different post-transplant maintenance therapies in 94 FLT3-ITD mutated r/r AML patients. A retrospective matched-pair analysis was performed. Patients were divided into two groups based on the maintenance therapy used, with 44 patients in the gilteritinib group and 50 patients in the control group (sorafenib/demethylating agents, or other targeted therapeutics were used as maintenance therapy). The therapeutic process and clinical outcome were retrospectively analyzed. Results: A total of 46.8% (44/94) of the patients had primary refractory disease and 42.6% (40/94) had recurrent AML. The remaining 10 patients were transplanted in CR1 but were detected with persistent MRD positivity during chemotherapy. Sixty-two patients (66.0%) were found to be MRD positive at the time of transplantation and 28 patients (29.8%) were transplanted with active disease. Gilteritinib maintenance therapy was associated with an improvement in overall survival (OS) (88.1% (95% CI 76.9-99.3%) vs. 65.1% (95% CI 51.6-78.6%), P=0.003) and relapse free survival (RFS) (75.7% (95% CI 62.6-88.8%) vs. 52.0% (95% CI 38.1-65.9%), P=0.006) at 2-years, when compared with the control group. Relapse remained the main reason of treatment failure with 2-year incidence of 25.4% (95%CI 12.7-40.2%) and 58.5% (95%CI 42.4-71.5%) for the gilteritinib group and the control group, respectively (P=0.004). Cumulative incidence of non-relapse mortality (NRM) at 2-years was similar (P= 0.744). In multivariate Cox regression analysis, gilteritinib maintenance therapy was the only factor associated with improved OS (HR=0.240, 95% CI 0.090–0.641, P=0.004) and RFS (HR=0.430, 95% CI 0.215–0.858, P=0.017). Cumulative incidence of day 100 aGVHD (P=0.083) and 2-year cGVHD (P=0.136) was comparable between the gilteritinib group and the control group. Summary/Conclusion: Our results indicated that gilteritinib maintenance therapy reduced the risk of relapse after HSCT for patients with FLT3-ITD mutated r/r AML. Compared with other maintenance therapies, gilteritinib treatment showed a similar incidence of NRM and GVHD, leading to an improvement in OS and RFS. Keywords: flt3 inhibitor, Maintenance, Allogeneic hematopoietic stem cell transplant, Acute myeloid leukemia

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
懵懂的映菱完成签到,获得积分10
刚刚
ccccc完成签到 ,获得积分10
刚刚
桃子汽水发布了新的文献求助10
刚刚
阳利发布了新的文献求助10
刚刚
科目三的应助被夏目采纳,获得20
刚刚
刚刚
紧张的道消完成签到 ,获得积分10
1秒前
1秒前
初景发布了新的文献求助10
1秒前
20030419ty2完成签到,获得积分10
1秒前
1秒前
lsx发布了新的文献求助10
1秒前
1秒前
屹男发布了新的文献求助10
1秒前
1秒前
米饭发布了新的文献求助10
2秒前
2秒前
今后的应助被科研通管家采纳,获得10
2秒前
桐桐的应助被科研通管家采纳,获得10
3秒前
orixero的应助被科研通管家采纳,获得10
3秒前
3秒前
桐桐的应助被科研通管家采纳,获得10
3秒前
Jun的应助被科研通管家采纳,获得20
3秒前
可爱的函函的应助被科研通管家采纳,获得200
3秒前
辽宁大学应用化学陈明完成签到 ,获得积分10
3秒前
彭于晏的应助被科研通管家采纳,获得10
3秒前
科研通AI65的应助被科研通管家采纳,获得10
3秒前
冻冻梨完成签到,获得积分10
3秒前
Orange的应助被科研通管家采纳,获得10
4秒前
英姑的应助被科研通管家采纳,获得10
4秒前
乐乐的应助被壮观梦易采纳,获得10
4秒前
null的应助被科研通管家采纳,获得10
4秒前
4秒前
DW的应助被科研通管家采纳,获得10
4秒前
风吹麦浪的应助被科研通管家采纳,获得10
4秒前
慕青的应助被科研通管家采纳,获得10
4秒前
汉堡包的应助被科研通管家采纳,获得10
4秒前
999发布了新的文献求助10
4秒前
Jun的应助被科研通管家采纳,获得20
5秒前
Hello的应助被科研通管家采纳,获得10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183739
求助须知:如何正确求助?哪些是违规求助? 9572996
关于积分的说明 21828615
捐赠科研通 7780904
什么是DOI,文献DOI怎么找? 3434101
关于科研通互助平台的介绍 2558294
邀请新用户注册赠送积分活动 2480564